natgillin/translations-raw huggingface dataset:
Studie V87P13 A/Vietnam/1194/2004 21 dage efter 2. dosis N=128
Study V87P13 A/Vietnam/1194/2004 21 days after 2nd dose N=128
Studie V87P13 A/Vietnam/1194/2004 21 dage efter 2. dosis N=69
Study V87P13 A/Vietnam/1194/2004 21 days after 2nd dose N=69
Studie V87P13 A/Vietnam/1194/2004 21 dage efter 2. dosis N=66
Study V87P13 A/Vietnam/1194/2004 21 days after 2nd dose N=66
Studie V87P13 A/Vietnam/1194/2004 21 dage efter 2. dosis N=143
Study V87P13 A/Vietnam/1194/2004 21 days after 2nd dose N=143
Administreres intramuskulært i deltamusklen.
To be administered intramuscularly into the deltoid muscle.
SØG LÆGE, hvis bivirkningerne varer ved.
If they persist, CONSULT YOUR DOCTOR.
*** GMR'er af SRH ° målt ved HI-analyse ≥ 40 °° GMR'er af HI
°° GMRs of HI
Serumbeskyttelsesrate (95 % CI)*
Seroconversion rate (95%CI)°
• Kramper
• Tingling
Det betyder, at der findes litteraturoplysninger, der danner videnskabelig dokumentation for virkning og sikkerhed ved denne anvendelse, og som dækker en periode på mindst 10 år i EU.
This means that there are bibliographic data providing scientific evidence of their effectiveness and safety when used in this way, covering a period of at least 10 years in the EU.
Lægemidler med ricinusolie bør kun anvendes til voksne og bør ikke anvendes i mere end en uge uden lægeligt tilsyn.
Castor oil medicines should only be used in adults, and should not be taken for longer than one week without medical supervision.
Dette betyder, at olien udvindes af frøene ved knusning og presning uden anvendelse af varme.
This means that the oil is extracted from the seeds by crushing and pressing them without heating.
Lægemidler med ricinusolie bør ikke anvendes under graviditet og amning.
They should not be used during pregnancy and breastfeeding.
Ansøgninger om godkendelse af lægemidler, der indeholder ricinusolie, skal indsendes til de nationale lægemiddelmyndigheder, som vurderer ansøgningen om plantelægemidlet og tager hensyn til HMPC's videnskabelige konklusioner.
Any applications for the licensing of medicines containing castor oil have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Ricinusolie er fællesnavnet for den olie, der fremstilles af frøene af planten Ricinus communis L. HMPC's konklusioner omfatter kun tilberedninger af ricinusolie, som fremstilles ved koldpresning af frøene.
Castor oil is the common name for the oil obtained from the seeds of the plant Ricinus communis L. The HMPC conclusions only cover castor oil preparations which are obtained by ‘cold expression' of the seeds.
Tilberedninger af ricinusolie findes desuden kombineret med andre droger i visse plantelægemidler.
Castor oil preparations may also be found in combination with other herbal substances in some herbal medicines.
Derved øges vandindholdet i afføringen, der bliver blødere og lettere at komme af med.
This increases the water content of stools, making them softer and easier to pass.
HMPC har i sin vurdering lagt vægt på to kliniske undersøgelser, der har påvist en afførende virkning ved lægemidler med ricinusolie hos patienter med forstoppelse.
In its assessment, the HMPC considered two clinical studies which showed a laxative effect for castor oil medicines in constipated patients.
Oplysninger om europæisk anvendelse og godkendelse af lægemidler, der indeholder ricinusolie, skal indhentes fra de relevante nationale myndigheder i EU's medlemsstater.
Information on the use and licensing of castor oil medicines in EU Member States should be obtained from the relevant national authorities.
Ved indtagelse nedbrydes ricinusolie til ricinolinsyre, der virker ved at mindske optaget af væske og salte i tyndtarmen (den øvre del af tarmsystemet).
When ingested, castor oil is broken down into ricinoleic acid which works by reducing absorption of fluid and salts in the small intestine (the upper part of the bowel).
Hvad er ricinusolie?
What is castor oil?
I en af undersøgelserne havde kapsler med ricinusolie samme virkning som kapsler med sennes (en anden drogetilberedning, der ofte anvendes til behandling af forstoppelse).
In one of the studies the effects of castor oil capsules were similar to those of senna capsules (another herbal preparation commonly used to treat constipation).
Yderligere oplysninger om HMPC's vurdering af lægemidler, der indeholder ricinusolie, herunder detaljerede oplysninger om udvalgets konklusioner, findes under fanebladet "All documents" på Det Europæiske Lægemiddelagenturs websted: ema.europa.eu/Find medicine/Herbal medicines for human use.
Further information on the HMPC assessment of castor oil medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Dette dokument er et sammendrag af Udvalget for Plantelægemidlers (HMPC) videnskabelige konklusioner angående den medicinske anvendelse af ricinusolie.
This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of castor oil.
Plantelægemidler med ricinusolie i disse tilberedninger fås normalt i fast eller flydende form til anvendelse gennem munden.
Herbal medicines containing these castor oil preparations are usually available in solid or liquid forms to be taken by mouth.
Detaljerede anvisninger på, hvordan lægemidler med ricinusolie bør anvendes, og hvem der kan bruge dem, findes i indlægssedlen i lægemiddelpakningen.
Detailed instructions on how to take castor oil medicines and who can use them can be found in the package leaflet that comes with the medicine.
Yderligere oplysninger om risici forbundet med lægemidler, der indeholder ricinusolie, herunder passende forholdsregler, der skal følges med henblik på sikker anvendelse, findes i monografien under fanebladet "All documents" på Det Europæiske Lægemiddelagenturs websted: ema.europa.eu/Find medicine/Herbal medicines for human use.
Further information on the risks associated with castor oil medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
HMPC har konkluderet, at ricinusolie i disse tilberedninger kan anvendes i kortere perioder som afføringsmiddel ved lejlighedsvis forstoppelse.
The HMPC concluded that these castor oil preparations can be used for short term as laxatives for occasional constipation.
HMPC's konklusioner om anvendelsen af lægemidler med ricinulolie som afføringsmiddel er baseret på den "almindeligt anerkendte anvendelse".
The HMPC conclusions on the use of these castor oil medicines as laxatives are based on their ‘wellestablished use'.
Disse bivirkninger omfatter kvalme, opkastning, mavesmerter og svær diarré.
These include nausea, vomiting abdominal (belly) pain and severe diarrhoea.
Lægemidler med ricinusolie bør ikke tages ved blokering eller forsnævring af tarmene, nedsat bevægelighed af tarmene, blindtarmsbetændelse, betændelsestilstande i tyktarmen (den nedre del af tarmsystemet), uforklarlige mavesmerter og svær væskemangel.
Castor oil medicines should not be taken in case of obstruction or narrowing of the gut, atony (loss of normal movement in the gut muscle), appendicitis (inflammation of the appendix, a small organ connected to the bowel), inflammatory diseases of the colon (the lower part of the bowel), unexplained abdominal pain and severe dehydration.
Hvordan godkendes lægemidler, der indeholder ricinusolie, i EU?
How are castor oil medicines approved in the EU?
Ricinusolie
Castor oil
Dette sammendrag er ikke en praktisk vejledning i, hvordan plantelægemidler, der indeholder ricinusolie, skal anvendes.
This summary is not intended to provide practical advice on how to use medicines containing castor oil.
Hvordan virker risinunolie som lægemiddel?
How does castor oil work as a medicine?
Andre oplysninger om lægemidler, der indeholder ricinusolie
Other information about castor oil medicines
Hvilken dokumentation underbygger den medicinske anvendelse af ricinusolie?
What evidence supports the use of castor oil medicines?
Hvilke risici er der forbundet med lægemidler, der indeholder ricinusolie?
What are the risks associated with castor oil medicines?
Hvis du ønsker yderligere oplysninger om behandling med lægemidler, der indeholder ricinusolie, kan du læse indlægssedlen, der ligger i lægemiddelpakningen, eller kontakte din læge eller dit apotek.
For more information about treatment with castor oil medicines, read the package leaflet that comes with the medicine or contact your doctor or pharmacist.
Derudover stimulerer ricinusolie tarmbevægelserne, hvilket også virker fremmende på afføringen.
In addition, castor oil stimulates movement in the intestines which will help to pass the stools.
Hvis du ønsker praktiske oplysninger om anvendelsen af lægemidler med ricinusolie, kan du læse indlægssedlen, der ligger i lægemiddelpakningen, eller kontakte din læge eller dit apotek.
For practical information about using castor oil medicines, patients should read the package leaflet that comes with the medicine or contact their doctor or pharmacist.
EU's medlemsstater tager hensyn til HMPC's konklusioner, når de vurderer ansøgninger om godkendelse af plantelægemidler, der indeholder ricinusolie.
Member States when evaluating applications for the licensing of herbal medicines containing castor oil.
Der er indberettet bivirkninger ved brug af lægemidler, der indeholder ricinusolie.
Side effects have been reported with castor oil.
(Særnavn) Navn Styrke Lægemiddelform Administration Emballage
MA (EU) number (Invented) name Strength Pharmaceutical form Route of administration Immediate Packaging Pack size EU/1/08/498/002 Thymanax
Betinget markedsføringstilladelse
Conditional marketing authorisation
<Similaritet>
<Similarity>
<Undtagelse>
<Derogation>
[For the conditional marketing authorisation status and, where appropriate, for similarity and derogation, please select the statement(s) as provided below.]
[For the conditional marketing authorisation status and, in case of similarity and an accepted derogation, please select the statement(s) as provided below.]
KONKLUSIONER VEDRØRENDE UDSTEDELSE AF MARKEDSFØRINGSTILLADELSE UNDER BETINGEDE OMSTÆNDIGHEDER OG <SIMILARITET> <OG> <UNDTAGELSE> <OG> <ANMODNING OM <MARKEDSFØRINGSBESKYTTELSE> <DATABESKYTTELSE> I ET ÅR> FREMLAGT AF DET EUROPÆISKE LÆGEMIDDELAGENTUR
CONCLUSIONS ON THE GRANTING OF THE CONDITIONAL MARKETING AUTHORISATION AND <SIMILARITY AND DEROGATION> <AND> < THE REQUEST FOR ONE-YEAR <MARKETING PROTECTION> <DATA EXCLUSIVITY>> PRESENTED BY THE EUROPEAN MEDICINES AGENCY
<indehaveren af markedsføringstilladelsen for {det godkendte lægemiddel til sjældne sygdomme} er ikke i stand til at levere tilstrækkelige mængder af lægemidlet> <og>
<the holder of the marketing authorisation for <authorised orphan medicinal product> is unable to supply sufficient quantities of the medicinal product> <and>
<indehaveren af markedsføringstilladelsen for {det godkendte lægemiddel til sjældne sygdomme} har givet sit samtykke til ansøgeren.>>
<the holder of the marketing authorisation for <authorised orphan medicinal product> has given his consent to the applicant.>
<CHMP er den opfattelse, at i henhold til artikel 8 i forordning (EC) nr. 141/2000 og <artikel 3 i Kommissionens forordning (EC) nr. 847/2000> [only for the superiority derogation] gælder følgende undtagelse(r), som fastlagt i samme forordnings artikel 8, stk. 3, og beskrevet nærmere i den europæiske offentlige vurderingsrapport:
<The CHMP is of the opinion that pursuant to Article 8 of Regulation (EC) No. 141/2000 and <Article 3 of Commission Regulation (EC) No 847/2000> [only for the superiority derogation] the following derogation
 laid down in Article 8.3 of the same Regulation apply(ies) as further explained in European Public Assessment Report :
<<Markedsføringsbeskyttelse><Databeskyttelse> i et år>
<one-year <marketing protection><data exclusivity>>
<ansøgeren kan i sin ansøgning påvise, at lægemidlet, selv om det er similært med {det godkendte lægemiddel til sjældne sygdomme, er sikrere, mere effektivt eller på anden vis klinisk overlegent (som defineret i artikel 3 i Kommissionens forordning (EC) nr. 847/2000) ved den samme terapeutiske indikation> <og>
<the applicant could establish in the application that the medicinal product, although similar to <authorised orphan medicinal product>, is safer, more effective or otherwise clinically superior (as defined in Article 3 of Commission Regulation (EC) No. 847/2000) for the same therapeutic indication> <and>
[For Art 14(11)] <CHMP gennemgik de oplysninger, som indehaveren af markedsføringstilladelsen havde indsendt, jf. artikel 14, stk. 11, i forordning (EC) nr. 726/2004, og er af den opfattelse, at den nye terapeutiske indikation giver en væsentlig klinisk fordel sammenlignet med eksisterende behandlinger.
[For Art 14(11)] <The CHMP reviewed the data submitted by the Marketing Authorisation Holder, taking into account the provisions of Article 14(11) of Regulation (EC) No 726/2004, and considers that the new therapeutic indication brings significant clinical benefit in comparison with existing therapies as further explained in the European Public Assessment Report.
[Art 10(5)] <CHMP gennemgik de oplysninger, som indehaveren af markedsføringstilladelsen havde indsendt, jf. artikel 10, stk. 5, i direktiv 2001/83/EC, og er af den opfattelse, at de <prækliniske undersøgelser> <og> <kliniske studier>, der er udført i forbindelse med den nye indikation, er af væsentlig betydning.
[Art 10(5)] <The CHMP reviewed the data submitted by the Marketing Authorisation Holder, taking into account the provisions of Article 10(5) of Directive 2001/83/EC, and considers that <the <pre-clinical tests> <and> <clinical studies> carried out in relation to the new indication were significant as further explained in the European Public Assessment Report.
<CHMP er af den opfattelse, at «lægemidlets navn» er similært med allerede godkendte lægemidler til sjældne sygdomme i henhold til artikel 3 i Kommissionens forordning (EC) nr. 847/2000.
<The CHMP is of the opinion that <name of product> is similar to authorised orphan medicinal products within the meaning of Article 3 of Commission Regulation (EC) No. 847/2000 as further explained in the European Public Assessment Report.
Storbritannien Waymade Plc Regency House
United Kingdom Waymade Plc Regency House
Storbritannien Generics (UK) Limited Station Close
United Kingdom Generics (UK) Limited Station Close
Grækenland PHARMACEUTICAL INDUSTRY PROEL EPAM.
PHARMACEUTICAL INDUSTRY PROEL EPAM.
Storbritannien Bristol Laboratories Limited Unit 3, Canal side
United Kingdom Bristol Laboratories Limited Unit 3, Canal side
Storbritannien RI Pharma Limited First floor,6 St John's Court Upper Fforest Way
United Kingdom RI Pharma Limited First floor,6 St John's Court Upper Fforest Way
Storbritannien Daichi-Sankyo UK Limited Chiltern Place
United Kingdom Daichi-Sankyo UK Limited Chiltern Place
Østrig ratiopharm Arzneimittel VertriebsGmbH Albert-Schweitzer-Gasse 3 1140 Vienna
Austria ratiopharm Arzneimittel VertriebsGmbH Albert-Schweitzer-Gasse 3 1140 Vienna
Ungarn ratiopharm Hungária Kereskedelmi Kft. Uzsoki u. 36/a
Hungary ratiopharm Hungária Kereskedelmi Kft. Uzsoki u. 36/a
Storbritannien Galen Limited Seagoe Industrial Estate Craigavon
United Kingdom Galen Limited Seagoe Industrial Estate Craigavon
Nederlandene Wise Pharmaceuticals Ltd. Hamwells Business Park Unit No. 7, Hardicker Street M19 2RB Manchester
The Netherlands Wise Pharmaceuticals Ltd. Hamwells Business Park Unit No. 7, Hardicker Street M19 2RB Manchester
Storbritannien Therabel pharma UK Limited Compass House, vision Park Chivers, Histon
United Kingdom Therabel pharma UK Limited Compass House, vision Park Chivers, Histon
Storbritannien Actavis UK Limited Whiddon Valley
United Kingdom Actavis UK Limited Whiddon Valley
Storbritannien Dexcel Pharma Limited 7 Sopwith Way
United Kingdom Dexcel Pharma Limited 7 Sopwith Way
Metamorfosi 14452
Metamorfosi 14452 Greece
Orale dråber, suspension
Oral drops, suspension
12th Km National Highway No 1, Metamorfosi Attikis 144 51
12th Km National Highway No 1, Metamorfosi Attikis 144 51 Greece
Grækenland MEDICUS S.A Valaoritou 10
MEDICUS S.A Valaoritou 10
Storbritannien Teva UK Limited Brampton Road
United Kingdom Teva UK Limited Brampton Road
Storbritannien Chelonia Healthcare Limited Boumpoulinas 11
United Kingdom Chelonia Healthcare Limited Boumpoulinas 11
Grækenland PHARMASWISS HELLAS A.E. Pentelis Avenue 53
PHARMASWISS HELLAS A.E. Pentelis Avenue 53
Orale dråber, solution
Oral drops, solution
Storbritannien Aptil Pharma limited 9th Floor
United Kingdom Aptil Pharma limited 9th Floor
Storbritannien Chiesi Limited Cheadle Royal Business Park Highfield, Cheadle Cheshire SK8 3GY United Kingdom
United Kingdom Chiesi Limited Cheadle Royal Business Park Highfield, Cheadle Cheshire SK8 3GY United Kingdom
Storbritannien Crescent Pharma Limited Unit 3&4
United Kingdom Crescent Pharma Limited Unit 3&4
Grækenland RAFARM AEBE Korinthou 12
RAFARM AEBE Korinthou 12
Storbritannien Pfizer Limited Ramsgate Road
United Kingdom Pfizer Limited Ramsgate Road
Storbritannien Focus Pharmaceuticals Limited Unit 5, Faraday court
United Kingdom Focus Pharmaceuticals Limited Unit 5, Faraday court
Grækenland NOVARTIS (HELLAS) A.E.B.E.
NOVARTIS (HELLAS) A.E.B.E.
N. Psychiko, 15451
N. Psychiko, 15451 Greece
Granulat til oral suspension
Granules for oral suspension
Storbritannien Chatfield Pharmaceuticals Limited
United Kingdom Chatfield Pharmaceuticals Limited
811 05 Bratislava Slovak Republic
811 05 Bratislava
Storbritannien Mercury Pharma Group Limited No. 1 Croydon
United Kingdom Mercury Pharma Group Limited No. 1 Croydon
Grækenland PHARMATHEN International S.A.Greece
PHARMATHEN International S.A.Greece
Storbritannien Co-Pharma Limited Unit 4, Metro Centre Tolpits Lane, Watford Hertfordshire WD18 9SS United Kingdom
United Kingdom Co-Pharma Limited Unit 4, Metro Centre Tolpits Lane, Watford Hertfordshire WD18 9SS United Kingdom
Intramuskulær injection eller intravenous infusion.
Intramuscular injection or intravenous infusion.
Storbritannien Ennogen Pharma Limited Unit G4, Riverside Way Dartford, DA1 5BS
United Kingdom Ennogen Pharma Limited Unit G4, Riverside Way Dartford, DA1 5BS
Diclofenackalium CATAFLAM ORAL DROPS 1.5%
Diclofenac potassium CATAFLAM ORAL DROPS 1.5%
Nederlandene Manston Pharma Limited 3 Montpelier Avenue, Bexley DA5 3AP Kent
The Netherlands Manston Pharma Limited 3 Montpelier Avenue, Bexley DA5 3AP Kent
Parenteral anvendelse;
Parenteral use;
Storbritannien Sandoz Limited Frimley Business Park Frimley
United Kingdom Sandoz Limited Frimley Business Park Frimley
Storbritannien Morningside Healthcare Limited 115 Narborough Road
United Kingdom Morningside Healthcare Limited 115 Narborough Road
Diclofenacnatrium POLYFLAM EX RUFIMAX EX
Diclofenac sodium POLYFLAM EX RUFIMAX EX
Diclofenacnatrium VOLTARENE ENFANT, suppositoire
Diclofenac sodium VOLTARENE ENFANT, suppositoire
Storbritannien Mercury Pharma International Limited
United Kingdom Mercury Pharma International Limited
12,5 mg Suppositorie
12,5mg Suppository
Diclofenacnatrium Diclo-B „Lannacher“Kapseln
Diclofenac sodium Diclo-B „Lannacher“Kapseln
TRATUL 120 mg 120 mg Suppositorie
TRATUL 120 mg 120mg
Depotkapsel, hård Oral anvendelse
Capsule, hard Oral use
Grækenland ANGELINI PHARMA HELLAS S.A. of Manufacturing and Commerce of Medicines Achaias & Trizinias
ANGELINI PHARMA HELLAS S.A. of Manufacturing and Commerce of Medicines Achaias & Trizinias Nea Kifissia 14564
Diclofenackalium Doble action pain relief
Diclofenac potassium Doble action pain relief
Diclofenackalium VOLTATABS 12,5 MG(EX:ZYMAMED)
Diclofenac potassium VOLTATABS 12,5 MG(EX:ZYMAMED)
Marathonos Avenue 106, Gerakas 15344
PHARMANEL COMMERCE PHARMACEUTICAL S.A. Marathonos Avenue 106, Gerakas 15344
Diclofenacnatrium VOLTAREN D DISPERSIBLE
Diclofenac sodium VOLTAREN D DISPERSIBLE
IBSA Slovakia s.r.o.
Slovak Republic IBSA Slovakia s.r.o.
Diclofenac Lidocain
Diclofenac Lidocaine
Mylan bvba Rozendal Businesspark Terhulpsesteenweg 6A B-1560 Hoeilaart Belgium
Belgium Mylan bvba Rozendal Businesspark Terhulpsesteenweg 6A B-1560 Hoeilaart Belgium
12,5 mg Kapsel, blød
12,5mg Capsule, soft
Diclofenacnatrium Diclo 100 retard - 1 A Pharma
Diclofenac sodium Diclo 100 retard - 1 A Pharma
Diclofenacnatrium Motifene Dual
Diclofenacum natricum Motifene Dual
Dispergibel tablet Oral anvendelse
Dispersible tablet Oral use
Storbritannien Novartis Consumer Health UK Limited
United Kingdom Novartis Consumer Health UK Limited
Diclofenacnatrium VOLTAREN SR SUSTAINED
Diclofenac sodium VOLTAREN SR SUSTAINED
Ikke til intravenous bolusinjektion
Not applicable for bolus intravenous injection
G. KORONIS Dilou 9, Peristeri
G. KORONIS Dilou 9, Peristeri Attikis, 12134
Tyskland hameln pharma plus gmbh Langes Feld 13
Prolonged-release tablet hameln pharma plus gmbh Langes Feld 13
Diclofenackalium Voltarol Pain-Eze Extra Strength
Diclofenac potassium Voltarol Pain-Eze Extra Strength
Diclofenacnatrium DICLAC 75 ID HEXAL SUSTAINED
Diclofenac sodium DICLAC 75 ID HEXAL SUSTAINED
Diclofenackalium Voltfast Sachets 50 mg Powder for Oral
Diclofenac potassium Voltfast Sachets 50 mg Powder for Oral
Storbritannien Actavis Group PTC ehf Reykjavikurvegi 76-78
United Kingdom Actavis Group PTC ehf Reykjavikurvegi 76-78
Diclofenacnatrium VOLTAREN DOLO FILM COATED
Diclofenac sodium VOLTAREN DOLO FILM COATED
Herbacos Recordati s.r.o.
Czech Republic Herbacos Recordati s.r.o.
Diclofenackalium Eminocs 50 mg/ml, drank
Diclofenac potassium Eminocs 50 mg/ml, drank
Granulat
Granules
Nederlandene Alfa Wassermann S.p.A.
The Netherlands Alfa Wassermann S.p.A.
Diclofenacnatrium Allvoran SF
Diclofenac sodium Allvoran SF
Nederlandene Actavis Group PTC ehf Reykjavikurvegi 76-78
The Netherlands Actavis Group PTC ehf Reykjavikurvegi 76-78
Diclofenacnatrium Olfen-75 SR Depotabs
Diclofenac sodium Olfen-75 SR Depotabs
Diclofenacnatrium DICLOFENAC DOC GENERICI
DICLOFENAC DOC GENERICI
Nederlandene Disphar International B.V.
The Netherlands Disphar International B.V. Winkelskamp 6
Diclofenacnatrium DICLOFENACO ALDO-UNION comprimidos EFG
Diclofenac sodium DICLOFENACO ALDO-UNION comprimidos EFG
Diclofenacnatrium Sandoz Ltd Diclovol SR Modified Release
Diclofenac sodium Sandoz Ltd Diclovol SR Modified Release
Diclofenacnatrium Mercury Pharms Econac SR Prolonged
Diclofenac sodium Mercury Pharms Econac SR Prolonged
Diclofenacnatrium RUVOMINOX
Diclofenac sodium RUVOMINOX
Diclofenacnatrium DiclacHexal rapid 50 mg - lösbare
Diclofenac sodium DiclacHexal rapid 50 mg - lösbare
Diclofenacnatrium Diclorapid 75 mg gastro-resistant capsules, hard
Diclofenacum natricum Diclorapid 75 mg gastro-resistant capsules, hard
Diclofenacnatrium REMETHAN SUSTAINED
Diclofenac sodium REMETHAN SUSTAINED
Diclofenacepolamin FLECTOR 25 mg, granulés pour solution buvable en sachet-dose
Diclofenac epolamine FLECTOR 25 mg, granulés pour solution buvable en sachet-dose
Diclofenacnatrium Mercury Pharms Econac XL Prolonged
Diclofenac sodium Mercury Pharms Econac XL Prolonged
Diclofenacepolamin FLECTOR 50 mg, granulés pour solution buvable en sachet-dose
Diclofenac epolamine FLECTOR 50 mg, granulés pour solution buvable en sachet-dose
Diclofenackalium Diclofenacratiopharm Lösung bei Migräne
Diclofenac potassium Diclofenacratiopharm Lösung bei Migräne
Diclofenackalium VOLTARENDOLO 12,5 mg, comprimé enrobé
Diclofenac potassium VOLTARENDOLO 12,5 mg, comprimé enrobé
Diclofenackalium VOLTAREN ACTIGO EXTRA
Diclofenac potassium VOLTAREN ACTIGO EXTRA
Diclofenackalium Diclo-CT akut 12,5 mg Filmtabletten
Diclofenac kalium Diclo-CT akut 12,5 mg Filmtabletten
Diclofenacnatrium Rewodina dual 75 Kaps
Diclofenac sodium Rewodina dual 75 Kaps
Diclofenacnatrium Diclo KD 75 akut
Diclofenac sodium Diclo KD 75 akut
Diclofenacnatrium Diclo 75mg prolonged release tablets.
Diclofenac sodium Diclo 75mg prolonged release tablets.
Diclofenacnatrium DICLOFENAC ALPHA BIOTECH
DICLOFENAC ALPHA BIOTECH
Nederlandene Apotex Europe B.V.
The Netherlands Apotex Europe B.V. Darwinweg 20
Diclofenaccolestyramin Voltaren resinat
Diclofenac colestyramin Voltaren Resinat